Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics

Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in treating moderate to severe plaque psoriasis i...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Mortato, F. Artosi, C. Borselli, I. Compagnucci, Antonia Rivieccio, C. Lanna, S. Lambiase, R. Gaeta Shumak, F. Loconsole, L. Bianchi, E. Campione
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Psoriasis
PASI
interleukin 17
bimekizumab
DLQI
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2432932
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2432932

Similar Items